Cipla gets VAI status for Virgonagar facility
Advertisement
Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the inspection at the Company’s manufacturing facility in Virgonagar, Bengaluru, India as Voluntary Action Indicated (“VAI”).
Medical Dialogues team had earlier reported that the Company had received eight observations from the USFDA for Virgonagar, Bengalur for the inspection conducted between 7th – 13th November, 2024.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.